Quimioterapia como tratamiento para CPCNP en los estadios más avanzados de la enfermedad

Author

Vila Casadesús, Arnau  

Abstract

Lung cancer is the leading cause of death worldwide, and the long-term survival rate for patients is one of the lowest of any other type of cancer. The main setbacks of this disease are detection in more advanced stages, nonspecific action, and resistance to the drugs supplied. This makes tumor recession more complex and unlikely. Despite drug and treatment innovations to address the drawbacks, lung cancer remains a deadly disease that requires new and effective treatment to give patients a better chance of survival. Currently, chemotherapy is the usual therapy in patients affected by NSCLC. The present study has been designed to provide an overview of chemotherapy and the main clinically accepted chemotherapeutic drugs used as a treatment for non-small cell lung cancer. In addition, this review allows us to know in a general way the characteristics and mechanisms of action of each of them and to hypothesize how the union between them could be, they know that the union does not
it turns out to have the same effect as the sum of the mechanisms of action separately.
The development of competent combination therapy, either between chemotherapeutic drugs or between therapies, alters resistance increasing effectiveness. Therefore, a possible combination therapy applicable mainly in the advanced stages of the disease is proposed in an experimental way.
The therapy proposed in this project is based on the combination of two types of cancer treatments, the cytostatic agent FdU10 with an mTOR siRNA. Both encapsulated using a relevant biomedical technique such as artificial nanocarrier synthesis. Specifically, a nanocarrier based on OM-pBAE that confers protection and cell specificity, reducing toxicity in healthy cells.

Director

Fornaguera Puigvert, Cristina
Borrós i Gómez, Salvador  

Degree

IQS SE - Undergraduate Program in Biotechnology

Date

2020-06-16